
CryoTherapeutics
Cryotherapies to prevent heart attacks.
EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
CryoTherapeutics is a medical device company focused on developing innovative intracoronary cryotherapy treatments for patients with high-risk plaque lesions, also known as vulnerable plaque, which can lead to heart attacks. Operating in the cardiovascular healthcare market, CryoTherapeutics aims to address the significant unmet need for interventional treatments that stabilize atherosclerotic plaque. The company's core product, the CTS system, delivers cryoenergy to the diseased parts of the artery, promoting arterial repair without the need for stents. This approach offers a novel solution for patients at high risk of heart attacks, as confirmed by diagnostic methods. CryoTherapeutics generates revenue through the development and eventual commercialization of its CTS system, targeting healthcare providers and institutions specializing in cardiovascular treatments. The company has recently secured new financing and commenced its first clinical study, focusing on refining the technology for broader clinical use.
Keywords: intracoronary cryotherapy, high-risk plaque, vulnerable plaque, heart attack prevention, arterial repair, cardiovascular healthcare, medical device, CTS system, clinical study, innovation.